Artwork

المحتوى المقدم من José-Alain Sahel. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة José-Alain Sahel أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
Player FM - تطبيق بودكاست
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !

Technological Innovation Liliane Bettencourt

مشاركة
 

سلسلة مؤرشفة ("تلقيمة معطلة" status)

When? This feed was archived on July 22, 2020 04:07 (4y ago). Last successful fetch was on April 07, 2020 16:42 (4+ y ago)

Why? تلقيمة معطلة status. لم تتمكن خوادمنا من جلب تلقيمة بودكاست صحيحة لفترة طويلة.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage series 1237296
المحتوى المقدم من José-Alain Sahel. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة José-Alain Sahel أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
José-Alain Sahel studied medicine at the Medical School of Paris University and ophthalmology at the University of Strasbourg and at Harvard University (Boston-Cambridge, USA). He was appointed Professor of Ophthalmology at the University Louis Pasteur, Strasbourg. Currently, José-Alain Sahel is Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris, France and Cumberlege Professor of Biomedical Sciences at the Institute of Ophthalmology-University College London, UK. He chairs the Departments of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation (Paris, France). The primary focus of Sahel’s fundamental and clinical research is the understanding of the mechanisms associated with retinal degeneration, together with the conception, development and evaluation of innovative treatments for retinal diseases, with a special focus on genetic rod-cone dystrophies (e.g. neuroprotection, stem cells, gene therapy, pharmacology, and artificial retina). The group of José-Alain Sahel (with Saddek Mohand-Said and Thierry Léveillard) was the first to hypothesize and demonstrate that rod photoreceptors produce a protein that rescues cone photoreceptors, thereby maintaining light-adapted and high-resolution vision. This molecule, Rod-derived Cone Viability Factor (RdCVF), is now in translation into a possible therapeutic agent to save cones and treat a spectrum of retinal degenerative diseases. Once rods and cones have degenerated, optogenetics -a promising novel therapeutic strategy- provides alternative to restore vision. Sahel‘s group (with Serge Picaud and Botond Roska at the Friedrich Miescher Institute for Biomedical Research) demonstrated that different retinal cell types such as “dormant cones” can be converted into “artificial photoreceptors” by targeting the expression of genetically encoded light sensors enabling mice with retinal degeneration to perform visually guided behaviors. Besides research on developmental biology, functional genomics, physiology and therapeutics, Sahel’s laboratory (with Michel Paques, Saddek Mohand-Said and Isabelle Audo) conducts research on genotype-phenotype correlations with high resolution in vivo non-invasive high-resolution retinal imaging techniques (optical coherence tomography and adaptive optics) aiming at identifying patients eligible for clinical application of innovative therapies. Together with Mathis Fink (Institut Langevin) he is the principal investigator of a very large ERC-synergy grant aiming at developing novel technologies for morpho-functional imaging of the visual system.
  continue reading

1 حلقة واحدة

Artwork
iconمشاركة
 

سلسلة مؤرشفة ("تلقيمة معطلة" status)

When? This feed was archived on July 22, 2020 04:07 (4y ago). Last successful fetch was on April 07, 2020 16:42 (4+ y ago)

Why? تلقيمة معطلة status. لم تتمكن خوادمنا من جلب تلقيمة بودكاست صحيحة لفترة طويلة.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

Manage series 1237296
المحتوى المقدم من José-Alain Sahel. يتم تحميل جميع محتويات البودكاست بما في ذلك الحلقات والرسومات وأوصاف البودكاست وتقديمها مباشرة بواسطة José-Alain Sahel أو شريك منصة البودكاست الخاص بهم. إذا كنت تعتقد أن شخصًا ما يستخدم عملك المحمي بحقوق الطبع والنشر دون إذنك، فيمكنك اتباع العملية الموضحة هنا https://ar.player.fm/legal.
José-Alain Sahel studied medicine at the Medical School of Paris University and ophthalmology at the University of Strasbourg and at Harvard University (Boston-Cambridge, USA). He was appointed Professor of Ophthalmology at the University Louis Pasteur, Strasbourg. Currently, José-Alain Sahel is Professor of Ophthalmology at Pierre and Marie Curie University Medical School, Paris, France and Cumberlege Professor of Biomedical Sciences at the Institute of Ophthalmology-University College London, UK. He chairs the Departments of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation (Paris, France). The primary focus of Sahel’s fundamental and clinical research is the understanding of the mechanisms associated with retinal degeneration, together with the conception, development and evaluation of innovative treatments for retinal diseases, with a special focus on genetic rod-cone dystrophies (e.g. neuroprotection, stem cells, gene therapy, pharmacology, and artificial retina). The group of José-Alain Sahel (with Saddek Mohand-Said and Thierry Léveillard) was the first to hypothesize and demonstrate that rod photoreceptors produce a protein that rescues cone photoreceptors, thereby maintaining light-adapted and high-resolution vision. This molecule, Rod-derived Cone Viability Factor (RdCVF), is now in translation into a possible therapeutic agent to save cones and treat a spectrum of retinal degenerative diseases. Once rods and cones have degenerated, optogenetics -a promising novel therapeutic strategy- provides alternative to restore vision. Sahel‘s group (with Serge Picaud and Botond Roska at the Friedrich Miescher Institute for Biomedical Research) demonstrated that different retinal cell types such as “dormant cones” can be converted into “artificial photoreceptors” by targeting the expression of genetically encoded light sensors enabling mice with retinal degeneration to perform visually guided behaviors. Besides research on developmental biology, functional genomics, physiology and therapeutics, Sahel’s laboratory (with Michel Paques, Saddek Mohand-Said and Isabelle Audo) conducts research on genotype-phenotype correlations with high resolution in vivo non-invasive high-resolution retinal imaging techniques (optical coherence tomography and adaptive optics) aiming at identifying patients eligible for clinical application of innovative therapies. Together with Mathis Fink (Institut Langevin) he is the principal investigator of a very large ERC-synergy grant aiming at developing novel technologies for morpho-functional imaging of the visual system.
  continue reading

1 حلقة واحدة

Tất cả các tập

×
 
Loading …

مرحبًا بك في مشغل أف ام!

يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.

 

دليل مرجعي سريع